Literature DB >> 3006245

Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera.

N C Kan, G Franchini, F Wong-Staal, G C DuBois, W G Robey, J A Lautenberger, T S Papas.   

Abstract

The nucleotide sequence of the genome of HTLV-III, the infectious agent etiologically associated with the acquired immune deficiency syndrome, predicts a small open reading frame, termed sor, located between the pol and env genes. A DNA segment containing 82 percent of the sor region was inserted into a prokaryotic expression vector, pJL6, to determine whether sor encodes a viral protein and to gain some insight into its possible function. The bacterially synthesized sor protein reacted with sera from individuals infected with HTLV-III, indicating that sor is expressed as a protein product or products that are immunogenic in vivo. Antibodies to the purified, bacterially synthesized sor protein were found to react specifically with the same protein and also with a protein of molecular weight 23,000 (23K) in HTLV-III-infected H9 cell extracts. The 23K protein comigrated with a protein immunoprecipitated by the serum of a hemophiliac patient with antibodies to HTLV-III, suggesting that this protein is probably the sor gene product.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3006245     DOI: 10.1126/science.3006245

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  38 in total

1.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.

Authors:  D H Gabuzda; K Lawrence; E Langhoff; E Terwilliger; T Dorfman; W A Haseltine; J Sodroski
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.

Authors:  Fei Guo; Shan Cen; Meijuan Niu; Jenan Saadatmand; Lawrence Kleiman
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 4.  Lentiviral Vif: viral hijacker of the ubiquitin-proteasome system.

Authors:  Elana S Ehrlich; Xiao-Fang Yu
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

5.  Differential response to the cytopathic effects of human T-cell lymphotropic virus type III (HTLV-III) superinfection in T4+ (helper) and T8+ (suppressor) T-cell clones transformed by HTLV-I.

Authors:  A De Rossi; G Franchini; A Aldovini; A Del Mistro; L Chieco-Bianchi; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

6.  Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus.

Authors:  B M Peterlin; P A Luciw; P J Barr; M D Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.

Authors:  Ying Dang; Xiaojun Wang; Ian A York; Yong-Hui Zheng
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

8.  Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1.

Authors:  J F Zagury; G Franchini; M Reitz; E Collalti; B Starcich; L Hall; K Fargnoli; L Jagodzinski; H G Guo; F Laure
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity.

Authors:  X Y Ma; P Sova; W Chao; D J Volsky
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions.

Authors:  M Dettenhofer; X F Yu
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.